Lactoferricin B (LfcinB) Dosage Calculator
Lactoferricin B is a 25-residue antimicrobial peptide (FKCRRWQWRMKKLGAPSITCVRRAF) derived from the N-terminal region of bovine lactoferrin through pepsin hydrolysis.
50mcg · Daily
Summary: Add 2mL BAC water to your 2mg vial. Draw to 5.0 units on a U-100 syringe for a 50mcg dose. This vial will last 40 doses.
Cycle Planner
Lactoferricin B (LfcinB) Pharmacokinetics
Pharmacokinetics — Active Dose Over Time
t½ = ~2-4 hours (estimated; rapid proteolytic degradation in vivo)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Lactoferricin B (LfcinB) Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 50mcg | Daily |
| Moderate | 100mcg | Daily |
| Aggressive | 200mcg | Daily |
Note: Lactoferricin B (LfcinB) is a 25-amino-acid cationic antimicrobial peptide (residues 17-41 of bovine lactoferrin) generated by pepsin cleavage. It contains an amphipathic beta-sheet stabilized by a single disulfide bond (Cys19-Cys36) and carries a net charge of approximately +8 at physiological pH. LfcinB demonstrates broader and more potent antimicrobial activity than its parent protein lactoferrin. It has been studied extensively for its direct membrane-disrupting mechanism against bacteria, fungi, and parasites, as well as its immunomodulatory and antitumor properties. Research use only — not approved for clinical use.
About Lactoferricin B (LfcinB)
Lactoferricin B is a 25-residue antimicrobial peptide (FKCRRWQWRMKKLGAPSITCVRRAF) derived from the N-terminal region of bovine lactoferrin through pepsin hydrolysis. First isolated and characterized in 1992 by Bellamy et al., it represents one of the most studied naturally derived antimicrobial peptides. The peptide adopts a twisted beta-sheet conformation in solution, stabilized by an intramolecular disulfide bridge. Its high cationic charge and amphipathic structure enable direct interaction with negatively charged microbial membranes, causing membrane permeabilization and cell death. Beyond antimicrobial activity, LfcinB exerts immunomodulatory effects by promoting macrophage and NK cell activation, and demonstrates selective cytotoxicity against cancer cell lines while sparing normal cells. These multifunctional properties have made it a subject of intense research in antimicrobial defense, cancer biology, and immune modulation.